Supreme Court Rules for Hikma, Weakening Patent Claims Tied to 'Skinny Labels'
The U.S. Supreme Court unanimously held that Hikma’s generic version of Amarin’s Vascepa did not infringe Amarin’s patents, rejecting a lower court ruling and potentially reducing the legal exposure of generic drugmakers that use so-called "skinny labels." The decision, supported by the Trump administration, centers on whether a generic manufacture…